#GRANULES | 🔮 ScoutQuest Crystal Ball
Future business outlook based on management commentary

Outlook: Management's future outlook includes near-term growth from new product launches in the CNS and ADHD segments in the US, though launches from the Gagillapur facility are on hold due to OAI status. Long-term growth aims for 20%+ CAGR through new launches, capacity expansion, new markets, dosage forms, and an enhanced oncology pipeline, with FY26 projected to improve significantly. FY26 Capex is forecasted at Rs.5 billion. Margin improvement is expected as one-time expenses decline, with EBITDA margins projected at 20-22%. Concerns include Gagillapur OAI status, API/PFI business pressures, and ongoing one-time expenses. Focus remains on quality, compliance, customer communication, and R&D investment.

Details:(ScoutQuest)

⚡ AI powered update byCheck-outto receive WhatsApp updates faster than twitter/X.
#GRANULES